Novo Nordisk ?Presents Phase 3 Data For Next-Generation Amylin Cagrilintide
I'm PortAI, I can summarize articles.
Sept 16 (Reuters) - Novo Nordisk A/S:* PRESENTS PHASE 3 DATA FOR NEXT-GENERATION AMYLIN CAGRILINTIDE* PRESENTED DATA FROM SUBANALYSIS OF PHASE 3 REDEFINE 1 TRIAL * RESULTS SHOW AVERAGE WEIGHT LOSS 12.5 KG WITH CAGRILINTIDE VERSUS 2.5 KG WITH PLACEBO AFTER 68 WEEKS* CAGRILINTIDE WAS WELL-TOLERATED * CAGRILINTIDE SIDE EFFECTS WERE GASTROINTESTINAL, TRANSIENT AND MILD TO MODERATE IN SEVERITY * TO ADVANCE CAGRILINTIDE INTO DEDICATED RENEW PHASE 3 CLINICAL PROGRAMME LATER THIS YEAR Further company coverage: (Gdansk Newsroom)
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments